Provided by Tiger Fintech (Singapore) Pte. Ltd.

COMPASS Pathways plc

3.56
-0.1500-4.04%
Pre-market: 3.54-0.0200-0.56%06:57 EDT
Volume:1.25M
Turnover:4.53M
Market Cap:333.08M
PE:-1.83
High:3.72
Open:3.71
Low:3.52
Close:3.71
Loading ...

Compass Pathways Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Compass Pathways Phase 3 trial delivers regulatory win, says H.C. Wainwright

TIPRANKS
·
Yesterday

COMPASS Pathways (CMPS) was downgraded to a Hold Rating at Evercore ISI

TIPRANKS
·
12 Jul

Compass Pathways Management to Discuss Innovations in Mental Health at HC Wainwright Interview

Reuters
·
11 Jul

Psychedelic: Exclusive talk with biotech company Compass Pathways

TIPRANKS
·
10 Jul

Cathie Wood’s ARK Investment buys 29K shares of Compass Pathways today

TIPRANKS
·
04 Jul

Compass Pathways plc Conducted Annual General Meeting

Reuters
·
30 Jun

Compass Pathways weakness a buying opportunity, says Canaccord

TIPRANKS
·
24 Jun

Compass Pathways Cut to In-Line From Outperform by Evercore ISI Group

Dow Jones
·
24 Jun

Compass Pathways results ‘historic first’ for psychedelics, says H.C. Wainwright

TIPRANKS
·
24 Jun

Crude Oil Falls 1%; US Services PMI Declines In June

Benzinga
·
24 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, Eli Lilly, Nuclear stocks

Reuters
·
23 Jun

Evercore ISI Downgrades COMPASS Pathways to In Line From Outperform

MT Newswires Live
·
23 Jun

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Evolent Health (EVH) and Tandem Diabetes Care (TNDM)

TIPRANKS
·
23 Jun

Compass Pathways Shares Down 38% After Depression Drug Study Data Disappoints Wall Street

THOMSON REUTERS
·
23 Jun

Compass Pathways Successfully Achieves Primary Endpoint In First Phase 3 Trial

Reuters
·
23 Jun

Compass Pathways Shares Down About 25% Premarket ; Co Reports Late-Stage Data From Experimental Depression Drug

THOMSON REUTERS
·
23 Jun

Compass Pathways' depression drug succeeds late-stage trial

Reuters
·
23 Jun

Compass Pathways Achieves Primary Endpoint in Phase 3 Trial for Psilocybin Treatment of Treatment-Resistant Depression

Reuters
·
23 Jun

Compass Pathways Plc - Comp006 Trial 26-Week Data Expected in Second Half of 2026

THOMSON REUTERS
·
23 Jun